Last Update: Aug 10, 2026 Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia ClinicalTrials.gov Identifier: [NCT06930859](https://clinicaltrials.gov/ct2/show/NCT06930859) Novartis Reference Number:CLEE011O1RU02 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This prospective, observational, multicenter study aims at evaluating the efficacy of adjuvant ribociclib in combination with hormone therapy (aromatase inhibitor ± GnRH aginost) in various subgroups of patients with HR+HER2- stage II-III breast cancer in real clinical practice in Russia. Subgroup division will be based on the tumor grade, lymph node involvement, and the response to test hormone therapy. The study will consist of two cohorts: a prospective one with patients receiving adjuvant therapy with ribociclib combined with Aromatase inhibitors (AI), and a retrospective one with patients receiving adjuvant therapy with AI alone. Thus, both primary data collection and secondary use of data will be organized. Condition Breast Cancer Overall Status Recruiting Number of Participants2766 Start Date Dec 03, 2025 Completion Date Dec 31, 2032 Gender All Age(s) 18 Years - 99 Years (Adult, Older Adult) ## Interventions Drug ### Anastrozole Aromatase inhibitor Drug ### Letrozole Aromatase inhibitor Drug ### Ribociclib CDK4/6 inhibitor ## Eligibility Criteria Inclusion Criteria: Patients from the prospective cohort of the study must meet all of the following criteria: 1\. Signed and dated Informed Consent Form (ICF) not later than 28 days after the initiation of adjuvant therapy with ribociclib in combination with aromatase inhibitors (±GnRH agonists). 2\. Age ≥18 years at the time of signing the ICF. 3\. Histologically verified HR+ HER2-negative stage II-III breast cancer, for which radical treatment was carried out. 4\. The adjuvant hormone therapy with aromatase inhibitors (±GnRH agonists) may be started not earlier than 12 months before initiation of therapy with ribociclib. 5\. ECOG performance status 0-1 Patients from the retrospective cohort of the study must meet all of the following criteria: 1\. Age ≥18 years at the initiation of hormone therapy. 2\. Histologically verified HR+ HER2-negative stage II-III breast cancer, for which radical treatment was carried out. 3\. Initiation of adjuvant hormone monotherapy with aromatase inhibitors (±GnRH agonists) in the index period from July 1, 2019 to July 1, 2020. 4\. Presence of the necessary information in the source documentation. Exclusion Criteria: Patients enrolled in the study in prospective cohort should not meet any of the following criteria. 1\. History of therapy with abemaciclib or palbociclib 2\. Therapy with ribociclib in combination with AI for more than 28 days at the time of signing the Informed Consent Form 3\. Active therapy for other malignant neoplasms 4\. Participation in interventional clinical studies at the time of signing the Informed Consent Form Patients enrolled in the study in retrospective cohort should not meet any of the following criteria. 1\. Neoadjuvant or adjuvant therapy with CDK4/6 inhibitors 2\. A history of another concomitant malignant neoplasm requiring active therapy 3\. Participation in interventional clinical studies at the time of treatment for breast cancer 4\. Patients experiencing a recurrence during adjuvant hormone therapy can participate if they meet the other inclusion and exclusion criteria. Russia #### Novartis Investigative Site Recruiting Perm,614066,Russia #### Novartis Investigative Site Recruiting Ufa,450054,Russia #### Novartis Investigative Site Recruiting Vladikavkaz,362002,Russia #### Novartis Investigative Site Recruiting Vladivostok,690105,Russia #### Novartis Investigative Site Recruiting Volgograd,400138,Russia #### Novartis Investigative Site Recruiting Yekaterinburg,620036,Russia #### Novartis Investigative Site Recruiting Moscow,115522,Russia #### Novartis Investigative Site Recruiting Moscow Region Balas,143900,Russia #### Novartis Investigative Site Recruiting Ryazan,Russia,390011,Russia #### Novartis Investigative Site Recruiting Khabarovsk,680042,Russia #### Novartis Investigative Site Recruiting Kirov,610021,Russia #### Novartis Investigative Site Recruiting Tyumen,625023,Russia #### Novartis Investigative Site Recruiting Voronezh,394036,Russia #### Novartis Investigative Site Recruiting Bryansk,241028,Russia #### Novartis Investigative Site Recruiting Khanty-Mansiysk,628012,Russia #### Novartis Investigative Site Recruiting Rostov-on-Don,344006,Russia #### Novartis Investigative Site Recruiting Pskov,Russia,180000,Russia #### Novartis Investigative Site Recruiting Sestroretsk,197706,Russia #### Novartis Investigative Site Recruiting Saint Petersburg,197758,Russia #### Novartis Investigative Site Recruiting Sochi,Russian Federation,354057,Russia #### Novartis Investigative Site Recruiting Saratov,410053,Russia #### Novartis Investigative Site Recruiting Yuzhno-Sakhalinsk,693010,Russia #### Novartis Investigative Site Recruiting Surgut,Tymen Area,628402,Russia #### Novartis Investigative Site Recruiting Barnaul,656045,Russia #### Novartis Investigative Site Recruiting Irkutsk,664035,Russia #### Novartis Investigative Site Recruiting Izhevsk,426009,Russia #### Novartis Investigative Site Recruiting Khimky,121552,Russia #### Novartis Investigative Site Recruiting Krasnoyarsk,660022,Russia #### Novartis Investigative Site Recruiting Saint Petersburg,194291,Russia #### Novartis Investigative Site Recruiting Saransk,430032,Russia #### Novartis Investigative Site Recruiting Tver',170008,Russia #### Novartis Investigative Site Recruiting Yaroslavl,150054,Russia #### Novartis Investigative Site Recruiting Kaluga,Russia,248007,Russia #### Novartis Investigative Site Recruiting Arkhangelsk,163045,Russia #### Novartis Investigative Site Recruiting Ivanovo,153040,Russia #### Novartis Investigative Site Recruiting Kemerovo,650036,Russia #### Novartis Investigative Site Recruiting Moscow,115304,Russia #### Novartis Investigative Site Recruiting Moscow,125284,Russia #### Novartis Investigative Site Recruiting Moscow,129110,Russia #### Novartis Investigative Site Recruiting Pyatigorsk,357502,Russia #### Novartis Investigative Site Recruiting Saint Petersburg,194017,Russia ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: